News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Navigating Fertility Misinformation on Social Media

December 26, 2024
By Miranda Schmalfuhs
Feature
Video

In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses the biggest misconceptions about fertility that he sees circulating on social media and work he does to correct and prevent them.

In this Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses the challenges of addressing fertility misinformation on social media. He emphasizes the importance of providing accurate and reliable information and encourages patients to consult with healthcare professionals. He also discusses the ethical considerations of using social media to share personal and professional experiences in the field of fertility.

What are the biggest misconceptions about fertility that you see circulating on social media? How do you work to correct these misconceptions and the spread of misinformation?

it's not an easy question to answer, Miranda. There are a lot of things that are packed into that comment. But let me start out by saying number one, I think that social media can be very, very beneficial in that it can impart an educational approach to fertility and fertility issues. On the flip side, you also know that there are many people who get on the social media, on TikTok, on Instagram, on whatever it may be, and tell stories that may or may not be factual.

Part of the problem that we deal with is that many times patients that we see come to us with questions that they've heard on TikTok or on Instagram or on Facebook or some social media aspect and are confused about what it really means. So, I think that the critical thing for us, and the thing that I typically do for me, is two things. Number one, when I meet with the patients, I try to give them an overview of what what goes on when they get evaluated by a fertility specialists and I try and explain to them what happens to them, what their evaluation is, what that evaluation means, and what their ultimate likelihood for success is depending on what they do.

The second thing I try to do is every Wednesday, at about 12:15pm I do a TikTok, which is called Wednesdays with the Werl. And when I do that TikTok, I effectively will pick a topic and will review that topic with the people who are involved on the TikTok, and then I open it up to questions. And maybe once a month, people have questions constantly. So once a month, I will actually do that Wednesdays with the world and only go through questions that people ask and try and answer them and give them the best answer that I can. I think the most important thing that I try to have patients take away from this is that one, it's educational, and two, what medicine is, is definitely a science.

But reproductive medicine is also an art, and how people do things can be different. My way of doing things is certainly my way of doing things, but it doesn't mean that it's the only way. There are other ways that you may approach a similar problem. It doesn't mean they're right or wrong. It just means that there are other ways to do things. And I think it's important, and I think it's important that when people go to these social media scenarios, that they take away from it, whatever it is they do, and then when they talk to their fertility physician — they can give them the pros and cons about what they ask. So, I think that's how hopefully I would try to approach it.

Recent Videos
Related Content

Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans

Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans

Don Tracy, Associate Editor
May 15th 2025
Article

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.


Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support

Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support

Don Tracy, Associate Editor
May 7th 2025
Article

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.


Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

Don Tracy, Associate Editor
April 30th 2025
Article

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.


Expanding Immune Response Testing to Support Vaccine Development

Expanding Immune Response Testing to Support Vaccine Development

Don Tracy, Associate Editor
April 22nd 2025
Article

Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.


Understanding Chronic Inflammation Through Viral Exposure

Understanding Chronic Inflammation Through Viral Exposure

Don Tracy, Associate Editor
April 21st 2025
Article

Nigel McCracken, chief operating officer, Virax Biolabs explains how the ViraxImmune PAIS assay uses T cell responses and cytokine levels to detect immune dysfunction and identify viral triggers of chronic inflammation.


New Insights Into T Cell Exhaustion and Inflammation in Long COVID

New Insights Into T Cell Exhaustion and Inflammation in Long COVID

Don Tracy, Associate Editor
April 17th 2025
Article

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.

Related Content

Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans

Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans

Don Tracy, Associate Editor
May 15th 2025
Article

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.


Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support

Asembia 2025: FDA Uncertainty Sparks Shift Toward Outsourced Pharma Support

Don Tracy, Associate Editor
May 7th 2025
Article

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services and outsourced support.


Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns

Don Tracy, Associate Editor
April 30th 2025
Article

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.


Expanding Immune Response Testing to Support Vaccine Development

Expanding Immune Response Testing to Support Vaccine Development

Don Tracy, Associate Editor
April 22nd 2025
Article

Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.


Understanding Chronic Inflammation Through Viral Exposure

Understanding Chronic Inflammation Through Viral Exposure

Don Tracy, Associate Editor
April 21st 2025
Article

Nigel McCracken, chief operating officer, Virax Biolabs explains how the ViraxImmune PAIS assay uses T cell responses and cytokine levels to detect immune dysfunction and identify viral triggers of chronic inflammation.


New Insights Into T Cell Exhaustion and Inflammation in Long COVID

New Insights Into T Cell Exhaustion and Inflammation in Long COVID

Don Tracy, Associate Editor
April 17th 2025
Article

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.